Effect of anti-CD38 monoclonal antibodies on hepatitis C virus replication in chronically infected patients with multiple myeloma: a prospective series

Click to increase image sizeClick to decrease image size

Acknowledgments

We thank Stephanie Deming, Research Medical Library, MD Anderson Cancer Center, for editing the manuscript. Dr. Manasanch would like to acknowledge support from Dr. Miriam and Sheldon G. Adelson Medical Research Foundation and the Paula and Rodger Riney Foundation.

Disclosure statement

MD Anderson Cancer Center is managing the terms of these arrangements in accordance with its conflict-of-interest policies. No potential conflict of interest was reported by the author(s).

Additional information

Funding

MD Anderson’s Institutional Review Board is supported by the NIH/NCI under award number P30CA016672. Dr. Torres is or has been the principal investigator for research grants from the National Cancer Institute, Gilead Sciences, and Merck & Co., Inc., with all funds paid to MD Anderson Cancer Center. Dr. Torres is or has been a paid scientific advisor for AbbVie, Inc., Gilead Sciences, Janssen Pharmaceuticals, Inc., Merck & Co., Inc., and Dynavax Technologies. Dr. Lee has received consulting fees from Bristol Myers Squibb, Celgene, Genentech, Karyopharm, Legend Biotech, GlaxoSmithKline, Sanofi, Pfizer, Monte Rosa Therapeutics, Oncopetides, Takeda Pharmaceuticals, Allogene Therapeutics and research funding: Amgen, Bristol Myers Squibb, Janssen, GlaxoSmithSkine, Regeneron, and Takeda Pharmaceutical. Dr. Manasanch has received research support from Sanofi, Quest Diagnostics, Novartis, JW Pharma, and Merck and consultant fees from Takeda, Celgene, Sanofi, GSK, Janssen, Telo Genomics, and Adaptive Biotechnologies.